December 17, 2018 7:56am
As the sector and overall stock market tends to consistently rise and fall over the short and near-term with alternating volatility and involuntary momentum contraction.
Out and about: Athersys (ATHX) extended the HEALIOS K.K.’s (Healios) exclusive period to negotiate an OPTION that would allow Healios to obtain a license for the development and commercialization of MultiStem therapy for certain indications in China. Healios has agreed to make a one-time $2 M payment for an extension through 6/30/19. Furthermore, Healios may make an additional payment of $3 M to extend the negotiation period for another six months through 12/31/19. All such payments would be creditable against the $15 million option fee that would be payable by Healios upon execution of the China option agreement, and milestones for any licensed program.
Pre-open indication: 5 BUY
I answer one question, in which company should investors put, keep and commit their money!
Members only. Please login.
